GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Amgen Inc.
Amgen is a pioneer in the biotech industry. Its stock price is driven by its R&D pipeline and the success of its existing drugs for cancer, bone disease, and cardiovascular disease. It's a classic story of growth driven by scientific innovation.
Share prices of companies in the market segment - Pharma holding
Amgen is a pioneer in the biotech industry, with segments in oncology, bone disease, and cardiovascular disease. We classify it as a Pharma holding, and the chart below shows the overall performance of the entire industry of large drugmakers.
Broad Market Index - GURU.Markets
Amgen is one of the world's first and largest biotech companies, with a strong portfolio of drugs across various fields. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. See how Amgen shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AMGN - Daily change in the company's share price Amgen Inc.
For Amgen, a pioneering biotech company, daily price changes are a measure of its response to clinical trial results and drug approvals. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Amgen Inc. is one of the pioneers and leaders in the biotech industry. This chart shows the average daily volatility of the entire sector. Comparing this to AMGN's performance helps us understand whether its portfolio of mature blockbusters and new drugs makes the company more or less stable than the industry as a whole.
Daily change in the price of a broad market stock, index - GURU.Markets
Amgen is one of the pioneers and leaders in the biotech industry. The pharmaceutical sector may operate by its own rules, but shares of such giants are still subject to overall market trends. The chart below shows overall market volatility, providing context for assessing Amgen's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Amgen Inc.
Amgen is a pioneer in the biotech industry. Its year-over-year growth reflects both sales of existing blockbusters and advances in new drug development, including promising obesity treatments that have become a new driver for the entire industry.
Annual dynamics of market capitalization of the market segment - Pharma holding
Amgen Inc. is a pioneer in the biotechnology industry. The company focuses on developing innovative drugs for the treatment of serious diseases. Its success depends on clinical trial results and the ability to bring new blockbusters to market, making its shares potentially more volatile than those of traditional pharmaceutical companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amgen is one of the oldest and largest biotech companies. Its growth depends on its existing pipeline and the success of new developments. For a mature biotech, it's important to demonstrate the ability to replenish its innovation pipeline. Its performance relative to the market reflects investor confidence in this process.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Amgen Inc.
The value of Amgen, one of the oldest biotech companies, depends on the life cycle of its drugs. The monthly fluctuations on the chart reflect sales data for existing drugs, clinical trial results for new developments, and competition from biosimilars for its key products.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart shows the dynamics of the entire pharmaceutical sector. For Amgen, a pioneering biotech company, it's the backdrop. It shows how the company, while managing a portfolio of mature blockbusters, is seeking new sources of growth through in-house development and major acquisitions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects overall market sentiment. For Amgen, one of the largest biotech companies, this is the backdrop. Its movements are typically less volatile than the market, demonstrating the defensive nature of its business, based on patented drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Amgen Inc.
Amgen Inc., a pioneering biotech company, sees its stock fluctuate weekly based on clinical trial results, FDA decisions, and sales news for its key drugs. This chart shows how investors evaluate its scientific pipeline and ability to compete in the pharmaceutical market.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Amgen, as one of the biotech industry's pioneers, often serves as a barometer. Its weekly performance can either align with overall trends or deviate from them due to news about clinical trials or M&A deals. The chart allows one to see whether this mature biotech is managing to outperform its younger, more aggressive competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Amgen is one of the oldest and largest biotech companies. Unlike young startups, Amgen has a portfolio of successful drugs and stable cash flow. The chart will show how its shares perform as a "defensive" asset, similar to classic Big Pharma.
Market capitalization of the company, segment and market as a whole
AMGN - Market capitalization of the company Amgen Inc.
Amgen's market capitalization chart tells the story of one of the pioneers of the biotech industry. Its price dynamics reflect the successes and failures of developing innovative drugs based on living organisms. Investors evaluate its portfolio of drugs for the treatment of oncology and chronic diseases, as well as its ability to expand it through research and acquisitions.
AMGN - Share of the company's market capitalization Amgen Inc. within the market segment - Pharma holding
Amgen is a pioneer and leader in the biotechnology industry. Its significant market share is driven by its portfolio of successful drugs for the treatment of oncology and chronic diseases. Its market capitalization reflects its innovative potential and ability to bring new drugs to market.
Market capitalization of the market segment - Pharma holding
Here's a chart reflecting the trillion-dollar value of the biotech sector. Amgen is one of its pioneers and leaders. The company specializes in developing innovative drugs based on living cells. The scale of this market, as you can see in the chart, reflects the hope that biotech will be able to overcome the most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Amgen is a pioneer in the biotech industry, developing innovative drugs to treat serious diseases. Its market value is based on its successful drugs and promising developments. The chart below shows the significant market share of biotech.
Book value capitalization of the company, segment and market as a whole
AMGN - Book value capitalization of the company Amgen Inc.
Amgen's foundation lies in its advanced biotech manufacturing facilities capable of producing complex protein therapeutics and its robust R&D centers. Its book value reflects the knowledge- and capital-intensive nature of its business. The graph is a financial reflection of the life cycle of its blockbuster drugs and investments in future hits.
AMGN - Share of the company's book capitalization Amgen Inc. within the market segment - Pharma holding
Boston Scientific creates high-tech medical devices that save lives. The chart shows the company's share of the sector's physical assets: sterile manufacturing facilities and R&D labs where stents, pacemakers, and other critical equipment are developed and manufactured.
Market segment balance sheet capitalization - Pharma holding
Amgen is a pioneer in biotechnology. Pharmaceuticals, as the chart shows, are capital-intensive. Amgen is a classic player, investing billions in R&D to create breakthrough drugs and building sophisticated factories to produce biological drugs.
Book value of all companies included in the broad market index - GURU.Markets
Amgen Inc. is a pioneer in the biotechnology industry. Its book value stems not only from its advanced manufacturing facilities for producing complex biologics but also from its valuable patent portfolio, which protects its blockbusters from competition.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Amgen Inc.
Amgen Inc. is a pioneer in biotechnology. The market pays a consistent premium to its assets for its portfolio of successful biologics, its manufacturing expertise, and its ability to generate massive cash flow, which it returns to shareholders.
Market to book capitalization ratio in a market segment - Pharma holding
Amgen is one of the world's oldest and largest biotech companies, specializing in the development of innovative drugs. Its value depends on the success of its scientific research and patent protection. This chart shows how investor expectations regarding its R&D pipeline and future blockbusters shape the premium on its manufacturing and research assets.
Market to book capitalization ratio for the market as a whole
Amgen is one of the world's first and largest biotechnology companies, specializing in the development of innovative drugs. Compared to average market valuations, as shown in this chart, Amgen's premium reflects the value of its pipeline and scientific potential, but also the risks associated with patent expirations and competition.
Debts of the company, segment and market as a whole
AMGN - Company debts Amgen Inc.
For Amgen, a pioneering biotech company, debt is a tool for funding both internal R&D and large strategic acquisitions. The $28 billion acquisition of Horizon Therapeutics was financed primarily with debt. This chart illustrates how the company uses leverage to expand its product portfolio.
Market segment debts - Pharma holding
Amgen is a pioneer in the biotech industry. To sustain growth, the company must continually invest in R&D and expand its drug portfolio, including through major acquisitions. These deals are often financed with significant debt. This chart shows how Amgen's M&A strategy impacts its financial structure and risk profile.
Market debt in general
Amgen is one of the world's first and largest biotech companies. Its success is based on developing innovative drugs to treat serious diseases. As with any pharmaceutical company, research requires significant investment. This total debt chart shows how aggressively Amgen uses leverage to fund R&D and acquisitions.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Amgen Inc.
Amgen is one of the oldest and largest biotech companies in the world. This chart shows how the company uses debt to finance its operations. Debt is often used to acquire other companies with promising drugs, to expand its pipeline, and to offset patent expirations on older drugs.
Market segment debt to market segment book capitalization - Pharma holding
Amgen is a pioneer in the biotech industry. The company's success depends on the development and commercialization of complex biologics. This chart shows how Amgen finances its expensive research. It compares its debt to the biotech industry's market capitalization, reflecting its growth strategy and financial risks.
Debt to book value of all companies in the market
Amgen, a pioneering biotech company, has significant financial resources. This chart compares its financial policies to the broader market. It shows that this mature biotech giant's debt burden is moderate compared to the average debt level across the economy, indicating its financial stability.
P/E of the company, segment and market as a whole
P/E - Amgen Inc.
This chart for Amgen, a pioneer in the biotech industry, shows how the market values a mature biotech company. Its P/E is based on the sales volume of its existing blockbuster drugs and investors' faith that its scientific research will lead to new successful anti-aging treatments.
P/E of the market segment - Pharma holding
Amgen is one of the world's oldest and largest biotech companies, specializing in developing innovative drugs to treat serious diseases. This chart shows the average valuation for the biotech sector, which is often valued at a premium for scientific potential. This helps understand how the market values Amgen's current and future pipeline.
P/E of the market as a whole
Amgen is one of the oldest and largest biotech companies in the world. Its valuation depends on the success of its drug portfolio and its ability to bring new innovative drugs to market. Amgen's business is less sensitive to short-term economic fluctuations, as reflected in this chart. Clinical trial results and regulatory decisions are far more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Amgen Inc.
Amgen is one of the oldest and largest biotech companies, specializing in developing innovative drugs for the treatment of serious diseases. This chart reflects investor expectations for its research pipeline. The company's valuation depends on sales forecasts for existing drugs and market confidence in the success of new developments in various stages of testing.
%20P%2FE%20Amgen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Amgen-Inc.&v=1772613098813 "Chart of the company's future (projected) P/E Amgen Inc.")
Future (projected) P/E of the market segment - Pharma holding
Amgen is one of the world's pioneering biotech companies, specializing in developing innovative drugs for the treatment of serious diseases. This chart reflects the market's assessment of its scientific potential and pipeline. Comparing its profit forecasts with the sector reveals how confident investors are in its future blockbusters.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772613098829 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Amgen is one of the world's oldest and largest biotech companies, specializing in the treatment of serious diseases. Its success is determined by scientific breakthroughs and the effectiveness of R&D. While the overall market backdrop shown in this chart is important, for Amgen and its investors, news from laboratories and clinics will always come first.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772613098862 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Amgen Inc.
Amgen Inc. is one of the oldest biotech companies, specializing in developing drugs to treat serious diseases. Its profits depend on sales of existing drugs and the success of clinical trials of new molecules. This graph reflects the product life cycle in biotech, where older blockbusters are expected to be replaced by new ones.
Profit of companies in the market segment - Pharma holding
Amgen is one of the oldest and largest biotechnology companies in the world. It is a pioneer in the development of recombinant DNA-based drugs and monoclonal antibodies. The success of its drugs in areas such as oncology and nephrology is a key driver of growth and profitability for the entire biotechnology sector.
Overall market profit
Amgen is a pioneering biotechnology company specializing in the development of recombinant DNA-based drugs. The company focuses on the treatment of serious diseases in oncology, cardiology, and inflammatory conditions. Amgen's success in developing innovative drugs demonstrates the potential of biotechnology to solve complex medical problems and create economic value.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Amgen Inc.
Amgen is one of the world's first biotech companies. Its profit projections, shown in this chart, are based on sales of its existing biologics portfolio and the success of new developments. The company actively uses M&A to expand its pipeline and ensure future growth.
%20profit%20of%20the%20company%20Amgen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Amgen-Inc.&v=1772613098979 "Graph of future (projected) profit of the company Amgen Inc.")
Future (predicted) profit of companies in the market segment - Pharma holding
Amgen is one of the first biotech companies to become a leader in developing drugs for the treatment of oncology and cardiovascular diseases. This chart reflects profitability forecasts for the entire biopharmaceutical industry. It allows one to compare the potential of Amgen's product portfolio with analysts' overall expectations for the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772613098981 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Biotech pioneer Amgen's profit forecast depends on sales of its key drugs and the success of its research and development. This chart reflects expectations for demand for drugs to treat oncology, cardiovascular, and inflammatory diseases, as well as the company's ability to expand its product portfolio through new developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772613099043 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Amgen Inc.
Amgen is one of the oldest biotech companies specializing in developing innovative drugs. This chart shows how investors value its revenue, which depends on its existing pipeline and the success of new developments. The multiple reflects the balance between mature products and future growth potential.
P/S market segment - Pharma holding
Amgen is one of the world's first and largest biotechnology companies, specializing in developing innovative drugs for the treatment of serious diseases. This metric reflects the average revenue estimate in the biotech sector and provides an insight into how investors perceive Amgen's drug portfolio and its research capabilities.
P/S of the market as a whole
Amgen is one of the oldest biotech companies, specializing in developing innovative drugs for the treatment of serious diseases. Its revenue depends on the success of its R&D and the life cycle of its patents. This chart, showing the average revenue estimate for Amgen, helps us understand how the market values its product portfolio and its ability to create new blockbusters.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Amgen Inc.
Amgen is one of the world's pioneering biotech companies, specializing in developing innovative drugs for the treatment of serious diseases. Its future depends on the success of clinical trials and the commercialization of new drugs. This chart reflects how investors assess Amgen's scientific potential and the commercial prospects of its development pipeline.
%20P%2FS%20Amgen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Amgen-Inc.&v=1772613099157 "The graph of the company's future (projected) P/S Amgen Inc.")
Future (projected) P/S of the market segment - Pharma holding
Amgen is one of the world's first and largest biotech companies. This chart shows how the market views its ability to develop and commercialize new innovative drugs. Do investors believe in its R&D pipeline and its ability to offset patent expirations on older blockbusters?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772613099212 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Amgen is one of the oldest and largest biotech companies in the world. Its revenue depends on the success of its drugs for serious diseases. Amgen's ability to develop and commercialize new drugs supports investor optimism about the entire sector, contributing to the overall positive growth expectations illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772613099314 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Amgen Inc.
Amgen is one of the first biotech companies to specialize in developing recombinant DNA-based drugs. Its revenue depends on sales of drugs for cancer, bone, and cardiovascular diseases. This chart reflects the commercial success of its innovative biologics.
Sales of companies in the market segment - Pharma holding
Amgen is one of the world's first and largest biotechnology companies, specializing in the development of drugs based on recombinant DNA and molecular biology. Its success is based on scientific breakthroughs. This chart shows total pharmaceutical sales, demonstrating the scale of the market in which Amgen competes through cutting-edge biotechnology.
Overall market sales
Amgen is one of the world's first and largest biotechnology companies, specializing in the development of recombinant DNA-based drugs. The company's growth depends on the success of its scientific research. This overall economic activity chart for Amgen, as for other pharmaceutical giants, is indirectly important through its impact on healthcare budgets and patient affordability.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Amgen Inc.
Amgen is one of the oldest and largest biotech companies in the world. Its future revenue depends on sales of its existing blockbuster drugs and the success of clinical trials of new drugs in its pipeline. This chart reflects analysts' forecasts for the commercial potential of Amgen's product portfolio and their belief in its R&D platform.
%20sales%20of%20the%20company%20Amgen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Amgen-Inc.&v=1772613099444 "Schedule of future (projected) sales of the company Amgen Inc.")
Future (projected) sales of companies in the market segment - Pharma holding
Amgen is one of the world's leading biotechnology companies, specializing in developing drugs to treat serious diseases. This chart displays projected revenues for the entire pharmaceutical sector. It provides insight into overall industry trends, which provides important context for assessing Amgen's research programs and the commercial potential of its drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772613099478 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Amgen is a pioneering biotechnology company specializing in the development of innovative medicines. Demand for its drugs to treat serious diseases is stable. However, the overall economic situation, shown in this chart, affects pricing and the ability of healthcare systems worldwide to reimburse the cost of expensive treatments, which is a key driver of Amgen's long-term growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772613099502 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Amgen Inc.
Amgen is one of the world's first and largest biotech companies, specializing in treating serious diseases. This chart shows the financial returns on successful biotech drugs. The company constantly faces the problem of patent expirations, and its long-term performance depends on the success of its R&D division.
Market segment marginality - Pharma holding
Amgen is a pioneering biotechnology company specializing in the development of innovative drugs for the treatment of serious diseases. Its success is based on scientific research and the ability to bring blockbuster drugs to market. This metric demonstrates how its portfolio of patented biologics enables the company to achieve profitability above the industry average.
Market marginality as a whole
Amgen is one of the oldest and largest biotech companies in the world, specializing in the development of recombinant DNA-based drugs. This chart shows the overall profit margin. It illustrates how scientific innovation can create entire markets and ensure high profitability thanks to patent protection for biologics.
Employees in the company, segment and market as a whole
Number of employees in the company Amgen Inc.
Amgen is a pioneer in the biotechnology industry, specializing in recombinant DNA drug development. This chart shows the size of the team of scientists and specialists working on innovative drugs. The increase in staff may be due to acquisitions to expand the company's pipeline and expansion of manufacturing capacity.
Share of the company's employees Amgen Inc. within the market segment - Pharma holding
This figure demonstrates Amgen's importance as a pioneer and leader in the biotechnology industry. Its significant share of employees in the sector reflects its deep expertise in developing complex biologic drugs for the treatment of serious diseases such as cancer and kidney failure. This represents human capital at the forefront of modern medicine.
Number of employees in the market segment - Pharma holding
Amgen is one of the world's first and largest biotech companies. Its focus on developing recombinant DNA-based drugs requires leading scientists in molecular biology and genetics. This chart illustrates the research-intensive nature of the biotech sector, where Amgen is a pioneer and one of the most prestigious places to work for researchers.
Number of employees in the market as a whole
Amgen is one of the world's first and largest biotechnology companies. Amgen specializes in developing complex (biological) drugs to treat serious diseases in oncology and immunology. This graph reflects the economic base that funds healthcare. Stable employment means more people have insurance that covers these innovative and expensive drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Amgen Inc. (AMGN)
Amgen is a pioneer in biotechnology. Its value is based on its portfolio of innovative biologics. Its high market capitalization per employee directly reflects the immense value of its patents and research, which leads to the creation of breakthrough drugs.
%20of%20the%20company%20Amgen%20Inc.%20(AMGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Amgen-Inc.-AMGN&v=1772613099788 "Chart of market capitalization per employee (in thousands of dollars) of the company Amgen Inc. (AMGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Amgen is a pioneering biotech company focused on complex biological drugs. This requires not only cutting-edge R&D but also highly sophisticated, specialized manufacturing (as opposed to simple chemical manufacturing). This metric reflects the market price per employee in this high-tech and capital-intensive scientific enterprise.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772613099813 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Amgen is one of the oldest and largest biotech companies in the world. The high market capitalization per employee, as shown in this chart, is a characteristic feature of the industry. It reflects the value of its portfolio of patented biologics, the development of which requires massive R&D investments but subsequently generates high profits.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772613099849 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Amgen Inc. (AMGN)
Amgen is a pioneer in biotechnology. The company focuses on developing drugs based on living cells rather than chemicals (like traditional pharmaceuticals). This chart shows the profitability of science-intensive R&D. Success in creating complex biological drugs (like Enbrel) provides the company with strong patents and high profits per scientist.
%20Chart%20Amgen%20Inc.%20(AMGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Amgen-Inc.-AMGN&v=1772613099942 "Company Profit Per Employee (in thousands of dollars) Chart Amgen Inc. (AMGN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Amgen is a pioneer in biotechnology. This chart shows the average for the pharmaceutical industry. This sector thrives on R&D and patents. The average return on employee profitability is high here, as a single successful drug patent can generate billions, more than offsetting R&D costs and ensuring high profits per scientist.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772613100140 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Amgen is one of the world's first and largest biotechnology companies. It specializes in developing drugs based on recombinant DNA and molecular biology. This metric demonstrates how its focus on cutting-edge science and the development of innovative drugs for the treatment of serious diseases delivers a high financial return on investment in R&D.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772613100173 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Amgen Inc. (AMGN)
Amgen is a pioneering biotech company specializing in the development of innovative drugs. This chart reflects a model where scientific breakthroughs are converted into high revenue. Successful, patent-protected drugs enable the company to generate significant revenue with a relatively small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Amgen-Inc.-AMGN&v=1772613100210 "Sales chart per company employee Amgen Inc. (AMGN)")
Sales per employee in the market segment - Pharma holding
Amgen is one of the first and largest biotech companies specializing in the treatment of oncology and inflammatory diseases. This chart shows the average revenue per employee in this segment, demonstrating how productive their scientific development and commercial efforts are compared to other major biopharmaceutical players.
Sales per employee for the market as a whole
Amgen is a pioneer in biotechnology. Unlike "chemistry" (small molecules), they specialize in "biology" (large molecules, proteins). Their business is creating innovative drugs for serious diseases. This chart, like that of all "big pharma," shows how investments in R&D and successful patents provide the company with high income per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Amgen Inc. (AMGN)
Amgen is one of the oldest biotech companies focused on treating serious diseases. The bearish sentiment seen in this chart may be related to concerns about "patent cliffs" (loss of exclusivity on older drugs) and doubts about whether new R&D will be able to offset lost revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Amgen-Inc.-AMGN&v=1772613100285 "Short Shares Chart for the Company Amgen Inc. (AMGN)")
Shares shorted by market segment - Pharma holding
Amgen is a pioneering biotech company specializing in drugs for the treatment of oncology, bone diseases, and inflammation. This chart shows the overall sentiment in the sector. It reflects investor concerns about drug pricing reforms in the US and increased competition in the biosimilar segment, which will impact the entire industry.
Shares shorted by the overall market
Amgen, a pioneering biotech company, is now a mature pharmaceutical company with a stable pipeline of drugs (for example, for osteoporosis) and new developments. This chart shows general fear. When it rises, investors seek "protection." Amgen's non-cyclical demand for drugs and its stable dividend make it an attractive asset during periods of uncertainty.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Amgen Inc. (AMGN)
Amgen is one of the oldest biotech companies with a mature pipeline and a strong focus on R&D. This indicator, above 70, may reflect the success of new developments or stable revenue. Oversold levels (<30) are often associated with concerns about patent expirations or clinical trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Amgen-Inc.-AMGN&v=1772613100460 "RSI 14 indicator chart for the company's stock Amgen Inc. (AMGN)")
RSI 14 Market Segment - Pharma holding
Amgen (AMGN) is one of the "fathers" of biotech. After years of steady growth, the company is seeking new drivers, including entering the highly profitable obesity drug market. This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand whether AMGN is overheated by expectations of a "new Ozempic" or is the overall biotech sector overheating?
RSI 14 for the overall market
Amgen is a pioneering biotech company specializing in drugs for the treatment of oncology, bone, and cardiovascular diseases. It's a story of scientific growth. This indicator measures the overall market environment, revealing when crowd panic or, conversely, euphoria is influencing perceptions of the "defensive" yet innovative biotech sector.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AMGN (Amgen Inc.)
This chart shows the collective opinion on Amgen. When setting target prices, analysts focus on its "old" blockbusters (Enbrel) and new growth drivers (e.g., obesity drugs). Their forecasts balance the risks of "patent cliffs" (loss of exclusivity) with the success of its R&D pipeline, which should offset these losses.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AMGN-Amgen-Inc.&v=1772613100638 "A chart showing analyst consensus forecasts for the expected stock price. AMGN (Amgen Inc.)")
The difference between the consensus estimate and the actual stock price AMGN (Amgen Inc.)
Amgen Inc. is a pioneering biotech company specializing in drugs for the treatment of oncology, bone, and cardiovascular diseases. This chart shows the gap between the consensus estimate and the price. It illustrates whether analysts believe in the company's R&D pipeline and its recent acquisitions (Horizon), seeing them as future sources of growth.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AMGN-Amgen-Inc.&v=1772613100757 "A chart showing the difference between the consensus forecast and the actual stock price. AMGN (Amgen Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Amgen is a pioneering biotech company specializing in the treatment of oncology, bone, and cardiovascular diseases. This chart shows analysts' overall expectations for the entire biotech sector. It reflects whether industry experts see new breakthroughs or believe the sector is facing pricing challenges.
Analysts' consensus forecast for the overall market share price
Amgen, a pioneer in biotech, is now a stable, defensive giant. Its drugs are needed in any weather. This chart shows the overall consensus forecast for the market. It helps understand what investors value more: protection (during a bearish price) or growth. During periods of panic, investors often park their money in stable stocks like Amgen.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Amgen Inc.
Amgen is a pioneer in the biotech industry. The company focuses on developing innovative drugs (biologicals, not chemicals) to treat serious diseases. This chart reflects the high degree of scientific risk and potential reward in biotech. It measures the market valuation of their current blockbusters and the confidence in their R&D pipeline.
AKIMA Market Segment Index - Pharma holding
Amgen is a biotech pioneer focused on treating serious diseases in oncology, cardiology, and immunology. This comprehensive index evaluates R&D. The chart shows the average value for the segment. This benchmark allows one to assess how Amgen's R&D pipeline and recent acquisitions differentiate it from the average pharma company.
The AKIM Index for the overall market
Amgen is one of the world's oldest and largest biotech companies, specializing in the development of innovative drugs in oncology, cardiology, and immunology. This chart, reflecting the market average, serves as a benchmark. It helps assess how Amgen, whose success depends on scientific breakthroughs and patent lifecycles, compares to overall macroeconomic trends, which typically have less of an impact on drug demand.
